Insulin Degludec vs PACAP-27

Head-to-head comparison of Insulin Degludec (Insulin degludec (desB30, acylated ultra-long-acting insulin analog)) and PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyInsulin DegludecPACAP-27
CategoryDiabetes & MetabolicDiabetes & Metabolic
Full NameInsulin degludec (desB30, acylated ultra-long-acting insulin analog)Pituitary Adenylate Cyclase-Activating Polypeptide-27
Molecular Weight6103.9 Da3158 Da
Half-LifeMore than 25 hoursminutes
Amino Acids5027
Typical Dose0.1-0.2 U/kg once dailyResearch-only: 0.1-1 nmol/kg
RouteSubcutaneousIntraperitoneal/Subcutaneous
Purity≥98%≥98%
Studies Count7000220
Research StatusApprovedPre-clinical

Insulin Degludec Benefits

  • Ultra-long basal coverage
  • Lower day-to-day variability
  • Reduced nocturnal hypoglycemia
  • Flexible dosing time

PACAP-27 Benefits

  • anti-apoptotic signaling
  • insulin secretagogue effect
  • reduced ER stress
  • islet cytoprotection

Insulin Degludec Dosing

Inject SC once daily|Titrate to fasting glucose and HbA1c response|May be administered with flexible timing in adults

PACAP-27 Dosing

0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing

Insulin Degludec Side Effects

  • Hypoglycemia
  • Injection-site reactions
  • Weight gain

PACAP-27 Side Effects

  • flushing
  • hypotension at high exposure
  • headache

Research Overview

Insulin Degludec

Studies highlight prolonged action and lower glycemic variability compared with many other basal insulins. It is frequently used in research on ultra-long basal coverage and hypoglycemia reduction.

PACAP-27

PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Insulin Degludec stacks with:

Insulin LisproInsulin Aspart

PACAP-27 stacks with:

GLP-1 analogsDPP-4 inhibitorsdiet and exercise
ultra-long-acting insulinbasal controllow variabilityneuropeptidebeta-cell protectioncAMP signaling